Bortezomib for the treatment of multiple myeloma

被引：18

作者：

Grosicki, Sebastian ^{[1
]}

Barchnicka, Agnieszka ^{[1
]}

Jurczyszyn, Artur ^{[2
]}

Grosicka, Anida ^{[3
]}

机构：

[1] Community Hosp Chorzow, Dept Hematol, Chorzow, Poland

[2] Univ Hosp, Dept Hematol, Krakow, Poland

[3] Silesian Med Univ, Dept Internal Med & Rheumatol, Katowice, Poland

来源：

EXPERT REVIEW OF HEMATOLOGY | 2014年 / 7卷 / 02期

关键词：

recommendations; safety; guidelines; multiple myeloma; bortezomib; treatment; proteosome inhibitor; efficacy; STEM-CELL TRANSPLANTATION; PEGYLATED LIPOSOMAL DOXORUBICIN; PROTEASOME INHIBITOR PS-341; RANDOMIZED PHASE-III; HIGH-DOSE MELPHALAN; INITIAL TREATMENT; IN-VIVO; THALIDOMIDE-DEXAMETHASONE; CONSOLIDATION THERAPY; PERIPHERAL NEUROPATHY;

D O I：

10.1586/17474086.2014.899144

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bortezomib is the first proteasome inhibitor drug tested in human patients. Bortezomib demonstrates a particular clinical utility in the treatment of multiple myeloma (MM), where it is the only one of the new drugs administered as mono-therapy that prolongs survival. The significant problem for the consistent pursuit of bortezomib was neurotoxicity, which has been significantly reduced by registering subcutaneous administration or being administered once per week. Bortezomib is currently approved for the treatment of patients with progressive MM in mono-therapy and in combination with prednisone and melphalan in cases of untreated patients who are not candidates for autologous hematopoietic stem cell transplantation (AHSCT) and in combination with dexamethasone or dexamethasone and thalidomide in untreated MM patients, who are candidates for treatment AHSCT. Clinical research is focused on the combination of bortezomib with other new drugs with the hope of further optimizing the treatment of patients with multiple myeloma.

引用

页码：173 / 185

页数：13

共 81 条

[1] Multiple Myeloma [J].

Anderson, Kenneth C. ;

Alsina, Melissa ;

Bensinger, William ;

Biermann, Sybil ;

Chanan-Khan, Asher ;

Cohen, Adam D. ;

Devine, Steven ;

Djulbegovic, Benjamin ;

Gasparetto, Cristina ;

Huff, Carol Ann ;

Jagasia, Madan ;

Medeiros, Bruno C. ;

Meredith, Ruby ;

Raje, Noopur ;

Schriber, Jeffrey ;

Singhal, Seema ;

Somlo, George ;

Stockerl-Goldstein, Keith ;

Tricot, Guido ;

Vose, Julie M. ;

Weber, Donna ;

Yahalom, Joachim ;

Yunus, Furhan .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (09) :908-942

[2]

[Anonymous], BLOOD

[3]

[Anonymous], 2008, VEL BORT INJ US PRES

[4] Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature [J].

Argyriou, Andreas A. ;

Iconomou, Gregoris ;

Kalofonos, Haralabos P. .

BLOOD, 2008, 112 (05) :1593-1599

[5] Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma [J].

Arnulf, Bertrand ;

Pylypenko, Halyna ;

Groslcki, Sebastian ;

Karamanesht, Ievgenii ;

Leleu, Xavier ;

van de Velde, Helgi ;

Feng, Huaibao ;

Cakana, Andrew ;

Deraedt, William ;

Moreau, Philippe .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (12) :1925-1928

[6] Single versus double autologous stem-cell transplantation for multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Facon, T ;

Guilhot, F ;

Doyen, C ;

Fuzibet, JG ;

Monconduit, M ;

Hulin, C ;

Caillot, D ;

Bouabdallah, R ;

Voillat, L ;

Sotto, JJ ;

Grosbois, B ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502

[7] A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients [J].

Berenson, James R. ;

Yellin, Ori ;

Chen, Chien-Shing ;

Patel, Ravi ;

Bessudo, Alberto ;

Boccia, Ralph V. ;

Yang, Hank H. ;

Vescio, Robert ;

Yung, Elizabeth ;

Mapes, Russell ;

Eades, Benjamin ;

Hilger, James D. ;

Wirtschafter, Eric ;

Hilger, Jacqueline ;

Nassir, Youram ;

Swift, Regina A. .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (05) :580-587

[8] Efficacy and safety of once-weekly bortezomib in multiple myeloma patients [J].

Bringhen, Sara ;

Larocca, Alessandra ;

Rossi, Davide ;

Cavalli, Maide ;

Genuardi, Mariella ;

Ria, Roberto ;

Gentili, Silvia ;

Patriarca, Francesca ;

Nozzoli, Chiara ;

Levi, Anna ;

Guglielmelli, Tommasina ;

Benevolo, Giulia ;

Callea, Vincenzo ;

Rizzo, Vincenzo ;

Cangialosi, Clotilde ;

Musto, Pellegrino ;

De Rosa, Luca ;

Liberati, Anna Marina ;

Grasso, Mariella ;

Falcone, Antonietta P. ;

Evangelista, Andrea ;

Cavo, Michele ;

Gaidano, Gianluca ;

Boccadoro, Mario ;

Palumbo, Antonio .

BLOOD, 2010, 116 (23) :4745-4753

[9] Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma [J].

Cavo, Michele ;

Pantani, Lucia ;

Petrucci, Maria Teresa ;

Patriarca, Francesca ;

Zamagni, Elena ;

Donnarumma, Daniela ;

Crippa, Claudia ;

Boccadoro, Mario ;

Perrone, Giulia ;

Falcone, Antonietta ;

Nozzoli, Chiara ;

Zambello, Renato ;

Masini, Luciano ;

Furlan, Anna ;

Brioli, Annamaria ;

Derudas, Daniele ;

Ballanti, Stelvio ;

Dessanti, Maria Laura ;

De Stefano, Valerio ;

Carella, Angelo Michele ;

Marcatti, Magda ;

Nozza, Andrea ;

Ferrara, Felicetto ;

Callea, Vincenzo ;

Califano, Catello ;

Pezzi, Annalisa ;

Baraldi, Anna ;

Grasso, Mariella ;

Musto, Pellegrino ;

Palumbo, Antonio .

BLOOD, 2012, 120 (01) :9-19

[10] Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21 [J].

Cayrol, C ;

Ducommun, B .

ONCOGENE, 1998, 17 (19) :2437-2444

← 1 2 3 4 5 6 7 8 9 →